FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531497072> ?p ?o ?g. }

• W2531497072 endingPage "238" @default.
• W2531497072 startingPage "228" @default.
• W2531497072 abstract "Peginterferon beta-1a 125 mcg administered subcutaneously every 2 weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved in January 2015 by the Scottish Medicines Consortium. This study assesses long-term clinical and economic outcomes of peginterferon beta-1a compared with other self-injectable DMTs (interferon beta-1a [22 mcg, 30 mcg, and 44 mcg], interferon beta-1b, and glatiramer acetate 20 mg) in the treatment of RRMS, from the National Health Service and Personal Social Services perspective in Scotland.A previously published, validated Markov cohort model was adapted for this analysis. The model estimates changes in patient disability, occurrence of relapses, and other adverse events, and translates them into quality-adjusted life years and costs. Natural history data came from the ADVANCE trial of peginterferon beta-1a, the London Ontario (Canada) database, and a large population-based MS survey in the UK. The comparative efficacy of each DMT vs placebo was obtained from a network meta-analysis. Costs (2015 British Pounds) were obtained from public databases and literature. Clinical and economic outcomes were projected over 30 years and discounted at 3.5% per year.Over 30 years, peginterferon beta-1a was dominant compared with interferon beta-1a (22, 30, and 44 mcg), and interferon beta-1b, and cost-effective compared with glatiramer acetate 20 mg. Results were most sensitive to variations in each DMT's efficacy and acquisition costs. Deterministic and probabilistic sensitivity analyses confirmed the robustness of the results.The impact of improved adherence with peginterferon beta-1a on clinical and economic outcomes and the impact of subsequent DMTs after treatment discontinuation were not considered. Oral and infused DMTs were not included as comparators. Conclusion Long-term treatment with peginterferon beta-1a improves clinical outcomes, while its cost profile makes it either dominant or cost-effective compared with other self-injectable DMTs for the treatment of RRMS in Scotland." @default.
• W2531497072 created "2016-10-21" @default.
• W2531497072 creator A5013282581 @default.
• W2531497072 creator A5036678805 @default.
• W2531497072 creator A5047452259 @default.
• W2531497072 creator A5059990105 @default.
• W2531497072 creator A5080992355 @default.
• W2531497072 date "2016-11-04" @default.
• W2531497072 modified "2023-09-28" @default.
• W2531497072 title "Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis" @default.
• W2531497072 cites W1512495229 @default.
• W2531497072 cites W1529192025 @default.
• W2531497072 cites W1581887055 @default.
• W2531497072 cites W1967838438 @default.
• W2531497072 cites W1973550674 @default.
• W2531497072 cites W1974859486 @default.
• W2531497072 cites W1975104912 @default.
• W2531497072 cites W1990918979 @default.
• W2531497072 cites W1997880566 @default.
• W2531497072 cites W2001446148 @default.
• W2531497072 cites W2005506388 @default.
• W2531497072 cites W2029836048 @default.
• W2531497072 cites W2046712471 @default.
• W2531497072 cites W2061166054 @default.
• W2531497072 cites W2063541285 @default.
• W2531497072 cites W2065910147 @default.
• W2531497072 cites W2072295861 @default.
• W2531497072 cites W2090486083 @default.
• W2531497072 cites W2103213691 @default.
• W2531497072 cites W2115989506 @default.
• W2531497072 cites W2125776201 @default.
• W2531497072 cites W2127622911 @default.
• W2531497072 cites W2129720713 @default.
• W2531497072 cites W2129967156 @default.
• W2531497072 cites W2136658595 @default.
• W2531497072 cites W2141621985 @default.
• W2531497072 cites W2143025931 @default.
• W2531497072 cites W2148370712 @default.
• W2531497072 cites W2153466844 @default.
• W2531497072 cites W2161512169 @default.
• W2531497072 cites W2166983650 @default.
• W2531497072 cites W2169098250 @default.
• W2531497072 cites W2171395509 @default.
• W2531497072 cites W2172271216 @default.
• W2531497072 cites W2294083275 @default.
• W2531497072 cites W2321043971 @default.
• W2531497072 cites W2331354957 @default.
• W2531497072 cites W2409482708 @default.
• W2531497072 cites W2704729794 @default.
• W2531497072 cites W33609267 @default.
• W2531497072 cites W4211254511 @default.
• W2531497072 cites W4366064463 @default.
• W2531497072 cites W579820641 @default.
• W2531497072 doi "https://doi.org/10.1080/13696998.2016.1247712" @default.
• W2531497072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27730845" @default.
• W2531497072 hasPublicationYear "2016" @default.
• W2531497072 type Work @default.
• W2531497072 sameAs 2531497072 @default.
• W2531497072 citedByCount "15" @default.
• W2531497072 countsByYear W25314970722017 @default.
• W2531497072 countsByYear W25314970722018 @default.
• W2531497072 countsByYear W25314970722019 @default.
• W2531497072 countsByYear W25314970722020 @default.
• W2531497072 countsByYear W25314970722021 @default.
• W2531497072 countsByYear W25314970722022 @default.
• W2531497072 crossrefType "journal-article" @default.
• W2531497072 hasAuthorship W2531497072A5013282581 @default.
• W2531497072 hasAuthorship W2531497072A5036678805 @default.
• W2531497072 hasAuthorship W2531497072A5047452259 @default.
• W2531497072 hasAuthorship W2531497072A5059990105 @default.
• W2531497072 hasAuthorship W2531497072A5080992355 @default.
• W2531497072 hasConcept C112930515 @default.
• W2531497072 hasConcept C126322002 @default.
• W2531497072 hasConcept C197934379 @default.
• W2531497072 hasConcept C203014093 @default.
• W2531497072 hasConcept C2778375690 @default.
• W2531497072 hasConcept C2778577042 @default.
• W2531497072 hasConcept C2780640218 @default.
• W2531497072 hasConcept C2908647359 @default.
• W2531497072 hasConcept C2908698914 @default.
• W2531497072 hasConcept C2910198813 @default.
• W2531497072 hasConcept C2994247566 @default.
• W2531497072 hasConcept C3019080777 @default.
• W2531497072 hasConcept C64332521 @default.
• W2531497072 hasConcept C71924100 @default.
• W2531497072 hasConcept C72563966 @default.
• W2531497072 hasConcept C99454951 @default.
• W2531497072 hasConceptScore W2531497072C112930515 @default.
• W2531497072 hasConceptScore W2531497072C126322002 @default.
• W2531497072 hasConceptScore W2531497072C197934379 @default.
• W2531497072 hasConceptScore W2531497072C203014093 @default.
• W2531497072 hasConceptScore W2531497072C2778375690 @default.
• W2531497072 hasConceptScore W2531497072C2778577042 @default.
• W2531497072 hasConceptScore W2531497072C2780640218 @default.
• W2531497072 hasConceptScore W2531497072C2908647359 @default.
• W2531497072 hasConceptScore W2531497072C2908698914 @default.
• W2531497072 hasConceptScore W2531497072C2910198813 @default.
• W2531497072 hasConceptScore W2531497072C2994247566 @default.

• next